|Bid||61.40 x 1000|
|Ask||61.62 x 800|
|Day's Range||61.29 - 62.40|
|52 Week Range||57.17 - 74.12|
|Beta (5Y Monthly)||0.38|
|PE Ratio (TTM)||17.27|
|Forward Dividend & Yield||2.92 (4.67%)|
|Ex-Dividend Date||Jun 14, 2022|
|1y Target Est||N/A|
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Gilead Sciences (GILD) closed at $62.21 in the latest trading session, marking a -0.99% move from the prior day.